SPOTLIGHT: Indian pharmas woo Romania's LaborMed

Three Indian pharma companies--Shreya Lifesciences, Dr. Reddy's Laboratories, and Lupin--are in the race to buy Romania's LaborMed, which markets some 80 products in that country. The price is expected to be around $100 million. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.